Opko Health, Inc.'s Citicoline Products Approved for Commercialization in Spain

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) announced that its Barcelona, Spain subsidiary, Pharmadiet, S.L.U., received regulatory approval from Spain’s health authority (Agencia Española de Medicamentos y Productos Sanitarios) for commercialization of its oral and injectable formulations of citicoline. Final marketing authorization is expected within 60 to 90 days. Sales of the other citicoline product presently available in Spain, Somazina®, exceeded $80 million in 2012. Citicoline also enjoys strong sales throughout Latin America, including those countries where OPKO maintains a growing presence.

Help employers find you! Check out all the jobs and post your resume.

Back to news